Lotte Biologics Signs Contract Development and Manufacturing Agreement for Anticancer Drug with Japanese Pharmaceutical Company
Production at Syracuse Bio Campus in the United States
Lotte Biologics announced on April 6 that it has signed a contract with a global pharmaceutical company based in Japan for the contract development and manufacturing of an anticancer drug candidate.
Based on this contract, Lotte Biologics plans to establish a strategic partnership in the development and production of biopharmaceuticals.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The company described this agreement as "the first collaboration based on mutual trust between the two companies" and stated, "We will accelerate efforts to strengthen our competitiveness in the global market, including Japan."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.